Clinical and economic burden of neurofibromatosis type 2 in the United States
Koo AB, Yeung JT, Freedman IG, Lee JH, Ahmed OM, Ma AK, Miyagishima DF, DiLuna M, Kahle K. Clinical and economic burden of neurofibromatosis type 2 in the United States. Clinical Neurology And Neurosurgery 2020, 197: 106053. PMID: 32683193, DOI: 10.1016/j.clineuro.2020.106053.Peer-Reviewed Original ResearchConceptsOpen resectionPatient demographicsRisk factorsMeningioma resectionMulti-year cross-sectional studyNeurofibromatosis type 2 (NF2) patientsSpine tumor resectionCommon admission diagnosesNational Inpatient SampleType 2 patientsCross-sectional studySignificant independent associationNeurofibromatosis type 2Regression analysisInflation-adjusted costAdmission diagnosisHospital stayDischarge weightIndependent predictorsObstructive hydrocephalusSurgical interventionDiagnosis codesHospital characteristicsInpatient populationInpatient SampleDoes neurofibromatosis 1 status impact outcomes for pediatric/young adults undergoing spinal fusion?
Freedman I, Koo A, Yeagle E, Diluna M, Kolb L, Yeung J. Does neurofibromatosis 1 status impact outcomes for pediatric/young adults undergoing spinal fusion? Surgical Neurology International 2020, 11: 60. PMID: 32363055, PMCID: PMC7193189, DOI: 10.25259/sni_39_2020.Peer-Reviewed Original ResearchNeurofibromatosis type 1Adverse postoperative eventsYoung adult patientsAdult patientsPostoperative eventsIndependent predictorsSpine patientsNF1 statusSpinal fusionNonroutine discharge dispositionNonroutine hospital dischargeFurther prospective studiesNationwide Inpatient SampleLength of staySignificant independent predictorsSpinal fusion surgeryYears of agePaucity of dataNonroutine dischargeMore transfusionsDischarge dispositionFusion patientsHospital dischargePerioperative variablesComplication rate